Chapter 4 - Discovery

24 Questions | Total Attempts: 175

SettingsSettingsSettings
Please wait...
Discovery Quizzes & Trivia

Chapter 4 - learning about Drug Discovery. Part 4 in your quest for knowledge.


Questions and Answers
  • 1. 
    What does NCE stand for? (exact spelling/wording for credit)
  • 2. 
    What is a "lead" compound?
    • A. 

      Another term for active pharmaceutical ingredient

    • B. 

      A compound that exhibits certain properties that suggest its value as a starting point for drug discovery

    • C. 

      A compound that is known to possess certain properties that suggest its value in clinical trials

    • D. 

      A compound made of lead, or, in latin, plumbum, atomic #82

  • 3. 
    When does true proof of concept (evidence that the drug is beneficial for the purpose being analyzed) occurs?
    • A. 

      Pre-clinical.

    • B. 

      Early Phase 1

    • C. 

      Early Phase 2

    • D. 

      In the discovery phase

  • 4. 
    What future advances may lead to increased effiency with regards to identifying promising lead compounds?
    • A. 

      A shift to fully automated R&D efforts

    • B. 

      A shift to gene and protien based targeting

    • C. 

      A shift to greater focus on isomers and alternative formulations of current blockbuster compounds

    • D. 

      Reverting back to manually determing the crystalline structures of lead compounds.

  • 5. 
    Discovery functions are aligned with ______________.Groups involved with discovery efforts are usually organized by ____________, and subdivided by __________.
    • A. 

      Therapeutic area, major process stages, scientific specialty

    • B. 

      Major process stages, scientific specialty, therapeutic area

    • C. 

      Scientific specialty, therapeutic area, major process stages

  • 6. 
    What does NME stand for? (exact spelling/wording for credit)
  • 7. 
    The journey of drug discovery begins with isolation of a ___________ and progresses to perfection of a ________.
    • A. 

      Disease, drug

    • B. 

      Target, lead compound

    • C. 

      Disease, lead compound

    • D. 

      Target, active ingredient

  • 8. 
    Discovery begins with the selction of a disease and a target. The target may be _________  in the market or completely ___________.
    • A. 

      In a new therapeutic area, or, a different class of drug entirely

    • B. 

      An isomer, or, a generic equivalent

    • C. 

      Previously established, or, new/innovative

    • D. 

      A bullleye or an X

  • 9. 
    Why is the discovery phase so important in controlling costs?
    • A. 

      This is where pharma companies identify promising compounds to be developed.

    • B. 

      This is where pharma companies identify less than promising coumpounds and eliminate them from cost-intensive development

    • C. 

      This is where drugs are discovered and is the basis for creating cash flow for the company as a whole.

    • D. 

      It isn't a factor in controlling costs.

  • 10. 
    How have certain facets of compound indetification been expedited in the modern day?
    • A. 

      The research teams have been diversified to bring input in from more types of scientists.

    • B. 

      The R&D teams have become more effective at manually identifying promising early stage compounds

    • C. 

      Researchers now use computer-based simulation and analysis to identify promising early stage compounds

    • D. 

      People are smarter now than they used to be.

  • 11. 
    What is the mission of drug discovery?
    • A. 

      To understand how a drug reacts on the body

    • B. 

      To determine the level at which the drug is toxic to create a safety threshold for patients using the drug.

    • C. 

      To improve the functioning of systems in the body by creating drugs that specifically target foreign antibodies.

    • D. 

      To understand the processes associated with a disease and to identigy a drug that can intervene in those processes

  • 12. 
    In vitro testing is _____________, while in vivo testing is _____________
    • A. 

      Harmful to the testing subject, not harmful to the testing subject

    • B. 

      Not harmful to the testing subject, harmful to the testing subject

    • C. 

      The testing in live animals, the testing of live tissue (from human or animal organs) in the lab

    • D. 

      The testing of live tissue (from human or animal organs) in the lab, the testing in live animals

  • 13. 
    Later-stage discovery involves:
    • A. 

      Discovering lead compounds at a later stage.

    • B. 

      Optimization of a set of molecules that appear to influence the target.

    • C. 

      Optimization of a target that shows promise.

    • D. 

      Discovering a secondary useage of a set of molecules/compounds during the optimization period.

  • 14. 
    Why do target profiles often get revised?
    • A. 

      In the event a secondary indication is discovered, it is necessary for the target profile to take into account the new usage.

    • B. 

      As time goes by, more data becomes available and it is necessary to revise the target profile to align with the new data.

    • C. 

      Because researchers realize that they were wrong in the first place.

    • D. 

      Side effects often occur in the discovery testing phase and it becomes evident that the drug is not an ideal candidate for a lead compound.

  • 15. 
    Why might a company elect not to continue to the development phase with a promising compound?
    • A. 

      Because it didnt reserve the patent in time so it would be a waste of money to develop the compound.

    • B. 

      Because the side effects outweight the benefits.

    • C. 

      Because it would be too expensive to develop the compound to a useable formulation.

    • D. 

      Because it does not align with the strategic goals of the company; and it becomes an outlicensing candidate.

  • 16. 
    Lead optimization is:
    • A. 

      The selection of the candidate with the most potential from the lead series/selecting a lead series out of a number of different compounds

    • B. 

      Optimizing the set of molecules/compound in order to indentify their potential.

    • C. 

      The minor modifications made to a team of sled dogs when a new team takes the lead at the Iditarod.

  • 17. 
    Why do Marketing and Discovery work so closely together?
    • A. 

      To develop marketing strategies based on the lead series the Discovery team has synthesized.

    • B. 

      To develop lead compounds that are based on the strategic goals of the company.

    • C. 

      To maintain a strong and clear messaging from discovery through to production.

    • D. 

      Come on, Beckett, they don't work closely together at all. Stop trying to trick me.

  • 18. 
    What is typically the primary research focus of R&D scientists?
    • A. 

      There is no focus, they're out to discover anything and everything.

    • B. 

      Focus is based on commercial imperative or a commitment to leveraging previously acquired intel.

    • C. 

      The focus is based on establishing generic bioequivalence.

    • D. 

      The primary focus is on the therapeutic area in which the pharma company competes.

  • 19. 
    At what point does the Discovery group apply for a patent?
    • A. 

      On day 1.

    • B. 

      When the lead compound(s) is/are identified.

    • C. 

      When the compound(s) begin/s to show promise

    • D. 

      When the full spectrum analysis con the compound/s has been conducted

  • 20. 
    What is pharmacogenomics?
    • A. 

      The study of gnomes involved with the illicit drug trade.

    • B. 

      The study of the pharmacology of genes.

    • C. 

      The study of the influence a cocktail of drugs on the entire genomic structure

    • D. 

      The study of genes and their relationship to drug action

  • 21. 
    Lead optimization includes all BUT:
    • A. 

      Testing of preliminary safety

    • B. 

      Pharmacology

    • C. 

      Pharmacokinetics

    • D. 

      Pharmacodynamics

    • E. 

      In vitro and in vivo testing

  • 22. 
    Once the target is identified, the ideal target product profile:
    • A. 

      Has both a high efficacy and level of side effects

    • B. 

      Optimally will combine high efficacy with a more favorable side effect profile

    • C. 

      Does not need to take into account the level of side effects if the condition is less serious

    • D. 

      Is a trade off between safety and efficacy.

  • 23. 
    True or False: Companies to not typically patent supporting research or manufacturing technologies.
    • A. 

      True

    • B. 

      False

  • 24. 
    If you are a BDM, please describe in a short paragraph how you would use the information you learned in this chapter in a sales meeting. What key concepts would you use to sell M Squared?If you are a CSM, please describe how you would use the information learned in this chapter to identify a good consultant and pitch the opportunity to them.If you are in Operations, you already do enough hard work. Please write "I am Operations. Hear me roar".
Back to Top Back to top